Press release article from our research archive:

MedPointe to Partner Newly Approved ZOMIG(R) (Zolmitriptan) Nasal Spray; AstraZeneca adds new, fast-acting dosage form to US migraine franchise marketed by MedPointe.

SOMERSET, N.J., Oct. 1 /PRNewswire/ -- MedPointe Inc., the specialty pharmaceutical company, has learned that AstraZeneca has received FDA approval of its new fast-acting migraine therapeutic, ZOMIG(R) (zolmitriptan) Nasal Spray (5.0mg), for the acute treatment of migraine with or without aura in adults. The nasal spray formulation is the newest addition to the ZOMIG product line, joining the conventional ZOMIG(R) (zolmitriptan) Tablets and the ZOMIG-ZMT(R) (zolmitriptan) Orally Disintegrating Tablets. As previously announced, beginning January 1, 2004, MedPointe will assume full responsibility in the U.S. for all ZOMIG(R) franchise sales, sales transactions, marketing, and ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!